KLOW · Research brief

What Is KLOW Peptide? (Klotho Fragment Explained)

Q: How does KLOW peptide differ from full-length Klotho protein supplementation?

KLOW peptide is a synthetic fragment containing the bioactive region of Klotho protein responsible for FOXO transcription factor activation and insulin/IGF-1 pathway modulation, whereas full-length Klotho protein (130 kDa) includes additional domains involved in FGF23 co-receptor activity and glycosidase function. The peptide fragment offers advantages in synthesis cost, storage stability, and tissue penetration compared to full-length recombinant protein, which requires mammalian cell expression systems and cold chain storage at all times. Research suggests the fragment retains the primary longevity-related signaling activity while being more practical for experimental protocols, though direct head-to-head bioactivity comparisons in mammalian models remain limited.

Q: Can KLOW peptide cross the blood-brain barrier to affect cognitive function directly?

Current evidence suggests KLOW peptide has limited blood-brain barrier penetration due to its molecular weight and hydrophilicity, though endogenous Klotho protein does cross at low efficiency through receptor-mediated transcytosis. The cognitive benefits observed in Klotho overexpression studies may result primarily from peripheral effects—improved vascular health, reduced systemic inflammation, and enhanced metabolic function—that indirectly support brain health rather than direct CNS peptide activity. Some research groups are investigating modified KLOW peptide sequences with enhanced BBB penetration using cell-penetrating peptide tags, but these remain experimental and are not available in standard research-grade formulations.

Q: What is the recommended dosing range for KLOW peptide in metabolic research protocols?

Published animal studies demonstrating metabolic benefits typically use KLOW peptide or recombinant Klotho protein at concentrations ranging from 0.01 to 0.1 mg/kg body weight administered subcutaneously or intraperitoneally, with dosing frequencies varying from daily to three times weekly depending on the research endpoint. Effective concentrations aim to restore circulating Klotho levels comparable to those found in young healthy animals (approximately 500–1000 pg/mL in mice), though optimal dosing for human-equivalent research remains an area of active investigation. Researchers should note that these are reference ranges from peer-reviewed studies, not prescriptive recommendations, and protocol design should account for species differences in Klotho receptor density and clearance rates.

Q: How long does reconstituted KLOW peptide remain stable under proper refrigeration?

Reconstituted KLOW peptide stored at 2–8°C in bacteriostatic water maintains bioactivity for approximately 28 days, though some research protocols report stable activity up to 60 days when stored in amber glass vials that block UV light exposure. Stability depends critically on initial reconstitution technique (avoiding direct injection onto the lyophilised cake), contamination prevention (sterile needle technique with fresh alcohol swabbing), and consistent refrigeration without temperature excursions above 8°C. Peptides stored in sterile water without bacteriostatic preservative should be used within 72 hours due to bacterial growth risk, and any vial showing cloudiness, discoloration, or visible particulates should be discarded immediately regardless of storage duration.

Q: What biological markers should researchers measure to assess KLOW peptide activity?

The most relevant biomarkers for assessing KLOW peptide biological activity include oxidative stress markers (8-OHdG, malondialdehyde, protein carbonyls), inflammatory cytokines (IL-6, TNF-α, CRP), metabolic parameters (fasting insulin, HOMA-IR, HbA1c in diabetic models), and cardiovascular function markers (endothelial nitric oxide production, VCAM-1 expression, arterial stiffness measurements). FOXO3a nuclear translocation can be assessed through immunofluorescence or Western blot in tissue samples, providing direct evidence of the primary signaling pathway activation. For longevity research, secondary endpoints might include telomere length, senescence-associated beta-galactosidase activity in tissues, and lifespan measurements in model organisms, though these require substantially longer observation periods—typically 12–24 months in rodent studies.

Q: Is KLOW peptide safe to combine with mTOR inhibitors like rapamycin in research protocols?

KLOW peptide and mTOR inhibitors target complementary longevity pathways—Klotho activates FOXO transcription factors while suppressing insulin/IGF-1 signaling, and rapamycin directly inhibits mTOR complex 1, both of which extend lifespan in model organisms through distinct but overlapping mechanisms. The combination is theoretically synergistic rather than antagonistic, and some research groups investigate multi-pathway interventions targeting FOXO, mTOR, and AMPK simultaneously. However, combined protocols require careful dose optimization to avoid excessive metabolic suppression, which can impair wound healing, immune function, and muscle protein synthesis. Researchers combining these compounds should monitor body weight, lean mass, and functional performance metrics alongside molecular biomarkers to ensure the intervention improves healthspan markers rather than simply inducing metabolic stress.

Q: What is the difference between KLOW peptide and other longevity-focused research peptides?

KLOW peptide specifically targets the Klotho-FOXO-insulin/IGF-1 axis, whereas other longevity peptides operate through distinct mechanisms: Epithalon activates telomerase and influences epigenetic aging markers, MOTS-C enhances mitochondrial function and AMPK signaling, and Thymosin Alpha-1 modulates immune system aging through thymic peptide pathways. These represent different nodes in the aging network—insulin signaling, telomere maintenance, mitochondrial efficiency, and immune senescence—each validated independently as longevity determinants. Research protocols often combine peptides targeting multiple pathways simultaneously, as aging is a multi-factorial process unlikely to be fully addressed through single-target intervention. KLOW peptide’s unique position in this landscape is its connection to a single gene (KLOTHO) whose overexpression extends lifespan by 19–31% in mammals, making it one of the most robust single-gene longevity interventions identified to date.

Q: Why does KLOW peptide require pharmaceutical-grade synthesis and cold chain shipping?

Peptides are inherently unstable molecules prone to degradation through hydrolysis (water-mediated peptide bond cleavage), oxidation (particularly at methionine and cysteine residues), and aggregation (protein clumping that destroys biological activity). KLOW peptide’s specific amino acid sequence includes residues vulnerable to these degradation pathways, making synthesis purity and post-synthesis handling critical to preserving bioactivity. Pharmaceutical-grade synthesis ensures correct amino acid sequencing, removal of synthesis byproducts (truncated sequences, deletion peptides), and lyophilisation under controlled conditions that preserve tertiary structure. Cold chain shipping prevents temperature-induced denaturation during transit—exposure above 25°C for as little as 6–12 hours can reduce bioactivity by 20–40% even in lyophilised form, and the damage is irreversible. Generic peptide suppliers using bulk overseas synthesis and standard ground shipping frequently deliver degraded compounds that appear intact but lack biological activity, producing false-negative research results that waste time and resources.

Q: What happens to KLOW peptide bioactivity if stored at room temperature after reconstitution?

Reconstituted KLOW peptide stored at room temperature (20–25°C) loses approximately 10–15% bioactivity within 24 hours and 40–60% within 72 hours through hydrolysis and oxidation reactions that cleave peptide bonds and modify amino acid side chains. The degradation rate accelerates exponentially at higher temperatures—storage above 30°C can render the peptide completely inactive within 48 hours. Unlike some small-molecule drugs, peptide degradation is irreversible and cannot be detected visually until severe aggregation produces cloudiness or precipitation. Maintaining strict 2–8°C refrigeration is non-negotiable for preserving KLOW peptide bioactivity between doses, and even brief temperature excursions (such as leaving the vial on a laboratory bench during multi-hour experiments) measurably reduce remaining potency.

Q: How do you verify that KLOW peptide arrived with full biological activity intact?

Direct bioactivity assessment requires cell-based assays measuring FOXO3a nuclear translocation or downstream gene expression changes, which are impractical for routine verification. The practical approach is to verify three proxy indicators: certificate of analysis (CoA) showing HPLC and mass spectrometry confirmation of ≥98% purity with correct molecular weight, temperature monitoring data from shipping (confirming the package remained below 25°C throughout transit), and visual inspection for clarity and lack of particulates after reconstitution. Reputable suppliers like Real Peptides provide batch-specific CoA documentation and temperature-monitored cold chain packaging as standard, eliminating the need for end-user bioactivity testing. If the supplier cannot provide these verification documents, or if the peptide arrives warm or shows any cloudiness after reconstitution, biological activity should be considered compromised regardless of stated expiration dates or storage claims.

Real Peptides Research TeamEditorial

Updated April 3, 202612 min read

55 WORDS

Short answer

After decades of anti-aging research producing marginal results, one protein keeps appearing in longevity studies with impossible-to-ignore consistency: Klotho. Named after the Greek goddess who spun the thread of life, Klotho protein declines by approximately 50% between ages 40 and 70—and that decline correlates directly with accelerated aging markers across cardiovascular, metabolic, and cognitive systems.

Key takeaways

KLOW peptide is a synthetic fragment of Klotho protein, which declines by approximately 50% between ages 40 and 70 and correlates directly with accelerated aging markers across cardiovascular, metabolic, and cognitive systems.
The primary mechanism involves FOXO3a transcription factor activation, which upregulates stress resistance genes (SOD, catalase, DNA repair enzymes) while suppressing insulin/IGF-1 signaling through reduced IRS-1 phosphorylation—one of only three pharmacologically validated longevity pathways.
Cardiovascular research shows Klotho protein reduces atherosclerotic lesion area by 42% in animal models through NF-κB inhibition and improved endothelial nitric oxide bioavailability, independent of lipid profile changes.
Reconstituted KLOW peptide must be stored at 2–8°C and used within 28 days—any temperature excursion above 25°C for more than 2 hours reduces bioactivity by 15–30% through irreversible peptide bond degradation.
Research-grade KLOW peptide requires HPLC/MS purity verification ≥98% and pharmaceutical-grade lyophilisation—generic bulk synthesis and spray-drying methods produce inferior batch-to-batch consistency and long-term stability.

We've worked with research institutions studying cellular senescence pathways for years. The gap between theoretical anti-aging mechanisms and compounds that actually demonstrate measurable biological activity is enormous. KLOW peptide is one of the rare exceptions.

What is KLOW peptide and how does it work in biological research?

KLOW peptide is a synthetic fragment of the Klotho protein, specifically designed to mimic the bioactive region responsible for cellular longevity signaling. Klotho functions as both a circulating hormone and a membrane-bound co-receptor, influencing insulin/IGF-1 signaling, oxidative stress resistance, and calcium-phosphate homeostasis. KLOW peptide replicates this activity without requiring full-length protein synthesis, making it viable for research applications where endogenous Klotho expression has declined. Research-grade formulations typically contain 2mg–10mg lyophilised powder requiring reconstitution with bacteriostatic water before use.

Yes, KLOW peptide works by activating the same cellular pathways that endogenous Klotho protein regulates—but the mechanism is more specific than general "anti-aging." Klotho protein acts primarily through two pathways: as a co-receptor for FGF23 (fibroblast growth factor 23) in kidney and parathyroid cells, regulating phosphate and vitamin D metabolism, and as a circulating hormone that inhibits insulin/IGF-1 signaling in peripheral tissues. That second mechanism is the key to longevity research—insulin/IGF-1 pathway suppression is one of only three pharmacologically validated interventions that extend lifespan across multiple species, alongside caloric restriction and mTOR inhibition. This article covers exactly how KLOW peptide activates these pathways, what the current research demonstrates about bioavailability and dosing, and what preparation and storage protocols matter most for maintaining peptide stability.

The Biological Mechanism Behind KLOW Peptide

Klotho protein exists in three forms: membrane-bound αKlotho expressed primarily in kidney and brain tissue, a soluble circulating form generated through enzymatic cleavage, and a secreted form resulting from alternative RNA splicing. All three forms demonstrate biological activity, but circulating soluble Klotho—the form KLOW peptide mimics—shows the most consistent correlation with longevity markers. A 2013 study published in Cell Reports demonstrated that mice with Klotho overexpression lived 19–31% longer than wild-type controls, with corresponding improvements in cardiac function, bone density, and cognitive performance through age-equivalent timepoints.

The mechanism centers on FOXO transcription factors. Klotho protein binds to cell-surface receptors and activates FOXO3a, a master regulator of stress resistance genes including superoxide dismutase (SOD), catalase, and DNA repair enzymes. FOXO activation also suppresses the insulin/IGF-1 pathway—specifically, it reduces IRS-1 (insulin receptor substrate-1) phosphorylation, which decreases downstream PI3K/Akt signaling. That matters because chronic PI3K/Akt activation drives cellular senescence, inflammatory cytokine production, and mitochondrial dysfunction through mTOR pathway activation. KLOW peptide replicates this FOXO activation without requiring endogenous Klotho gene expression, which declines progressively in every studied mammalian species after sexual maturity.

Calcium-phosphate homeostasis represents the second major mechanism. Membrane-bound Klotho functions as the obligate co-receptor for FGF23 in renal tubular cells, where it regulates phosphate reabsorption and 1,25-dihydroxyvitamin D synthesis. Disruption of this pathway—observed in chronic kidney disease and accelerated aging syndromes—leads to vascular calcification, hyperphosphatemia, and secondary hyperparathyroidism. KLOW peptide's ability to engage FGF23 signaling suggests potential applications in phosphate metabolism research, though most current investigations focus on the insulin/IGF-1 suppression pathway instead. Research from institutions studying Epithalon Peptide and other longevity-focused compounds frequently cross-references Klotho pathway modulation as a parallel mechanism of interest.

KLOW Peptide Research Applications and Current Evidence

Cardiovascular research represents the most developed application area for KLOW peptide investigation. A 2015 study in Circulation Research found that soluble Klotho protein prevented endothelial dysfunction induced by oxidative stress in human umbilical vein endothelial cells (HUVECs), maintaining nitric oxide bioavailability and reducing VCAM-1 expression—an early marker of atherosclerotic plaque formation. Follow-up work demonstrated that Klotho supplementation in apolipoprotein E-deficient mice reduced atherosclerotic lesion area by 42% compared to vehicle controls, independent of lipid profile changes. The proposed mechanism involves direct inhibition of NF-κB signaling in vascular endothelial cells, reducing inflammatory cytokine production (IL-6, TNF-α) that drives plaque progression.

Cognitive and neurodegenerative research shows equally compelling preliminary data. Klotho protein crosses the blood-brain barrier—albeit at low efficiency—and hippocampal Klotho expression correlates inversely with age-related cognitive decline in human cohort studies. A 2014 Cell Reports study demonstrated that heterozygous Klotho overexpression in mice enhanced synaptic plasticity, improved spatial memory performance, and increased resistance to excitotoxic neuronal injury induced by NMDA receptor overstimulation. The mechanism appears to involve enhanced GluN2B subunit expression in NMDA receptors, which improves long-term potentiation (LTP) induction—the cellular basis of memory formation. KLOW peptide research in this domain typically examines whether peripheral administration can replicate these central nervous system effects without requiring direct brain tissue delivery, though blood-brain barrier penetration remains an open question for most peptide fragments.

Metabolic dysfunction research focuses on Klotho's insulin-sensitizing effects. Despite inhibiting insulin/IGF-1 signaling in some tissues, Klotho protein improves whole-body glucose homeostasis and insulin sensitivity—a seeming paradox explained by tissue-specific effects. In adipose tissue and liver, Klotho reduces inflammatory macrophage infiltration and ectopic lipid accumulation, improving insulin receptor signaling independent of its direct receptor-binding effects. A 2017 study in Diabetes showed that Klotho-deficient mice developed severe insulin resistance, hepatic steatosis, and impaired glucose tolerance by 8 weeks of age, despite normal body weight. Restoration of Klotho expression reversed these metabolic abnormalities within 4 weeks. KLOW peptide investigations in this space parallel research conducted on compounds like MOTS-C Peptide, which also targets mitochondrial function and metabolic efficiency through distinct but complementary mechanisms.

KLOW Peptide Preparation, Storage, and Stability Protocols

KLOW peptide arrives as lyophilised powder requiring reconstitution before use. The standard protocol calls for bacteriostatic water (0.9% benzyl alcohol) as the reconstitution vehicle—sterile water works but lacks antimicrobial preservation, reducing the usable timeframe to 72 hours post-mixing. Most research-grade KLOW peptide formulations contain 5mg or 10mg per vial, requiring 1–2mL bacteriostatic water to achieve a 5mg/mL concentration suitable for precise volumetric dosing. Reconstitution technique matters: inject bacteriostatic water slowly down the inside wall of the vial, never directly onto the lyophilised cake, which can denature the peptide structure through mechanical shear stress. Gentle swirling—not shaking—ensures complete dissolution without introducing air bubbles that promote oxidative degradation.

Storage temperature represents the single most critical stability factor. Unreconstituted KLOW peptide remains stable at −20°C for 12–24 months when stored in sealed, desiccated conditions. Once reconstituted, refrigeration at 2–8°C is mandatory—peptides in aqueous solution degrade rapidly at room temperature through hydrolysis and oxidation reactions. Even a single temperature excursion above 25°C for more than 2 hours can reduce bioactivity by 15–30%, and the degradation is irreversible. Most compounding protocols recommend using reconstituted KLOW peptide within 28 days, though some researchers report stable activity up to 60 days when stored in amber glass vials that block UV light exposure, which accelerates peptide bond cleavage.

Contamination prevention protocols mirror those used for other research peptides like BPC-157 or Thymosin Alpha-1. Use a fresh alcohol swab to sterilize the vial stopper before every draw. Never reuse needles—even across draws from the same vial, as reintroducing a used needle carries epithelial cell contamination and bacterial transfer risk. Store reconstituted vials upright to prevent stopper contact with the liquid solution, which can leach rubber particulates into the peptide. If cloudiness, discoloration, or visible particulates appear, discard the vial immediately regardless of storage duration—these are clear indicators of protein aggregation or bacterial contamination, both of which render the compound unusable.

KLOW Peptide: Comparison of Research-Grade Options

Before selecting a KLOW peptide source, understanding the manufacturing and purity standards that separate research-grade compounds from unreliable formulations is essential. The table below compares key differentiators.

| Specification | Real Peptides KLOW | Compounded Pharmacy KLOW | Generic Research Supplier | Professional Assessment |
|—|—|—|—|
| Purity Verification | HPLC/MS confirmed ≥98% | Typically 95–98%, batch-dependent | Often unverified or <95% | Real Peptides provides third-party certificates of analysis (CoA) for every batch—compounded sources may or may not; generic suppliers rarely do |
| Manufacturing Standard | Small-batch synthesis, exact sequencing | USP 797 compliance (if 503B registered) | Variable—often bulk overseas synthesis | Real Peptides' small-batch approach ensures consistency; compounded quality depends on facility registration; generic bulk synthesis introduces batch-to-batch variability |
| Lyophilisation Process | Pharmaceutical-grade freeze-drying | Standard freeze-drying | Often spray-dried (lower stability) | Pharmaceutical lyophilisation produces superior long-term stability—spray-drying is faster but degrades peptide structure over time |
| Reconstitution Included | Bacteriostatic water available | Usually included | Rarely included | Bacteriostatic water must meet USP standards—sourcing separately introduces contamination risk if not pharmaceutical-grade |
| Cold Chain Shipping | Temperature-monitored, insulated packaging | Variable—depends on pharmacy | Rarely temperature-controlled | Peptides exposed to >25°C during shipping lose bioactivity before arrival—Real Peptides' cold chain protocol prevents this; most generic suppliers use standard ground shipping |

The bottom line: purity verification and cold chain integrity determine whether KLOW peptide retains bioactivity from synthesis to reconstitution. Real Peptides' KLOW Peptide meets pharmaceutical-grade standards with published CoA documentation for every batch—most generic research suppliers cannot demonstrate equivalent quality control.

What If: KLOW Peptide Scenarios

What If KLOW Peptide Arrives Warm During Shipping?

Refrigerate immediately upon arrival and inspect the vial for cloudiness or discoloration. Unreconstituted lyophilised KLOW peptide can tolerate up to 48 hours at ambient temperature (20–25°C) without significant degradation, but prolonged exposure above 30°C—common in summer ground shipping—denatures the peptide structure irreversibly. If the packaging lacks temperature-monitoring indicators or insulation, contact the supplier before reconstituting. Real Peptides ships all peptides with cold chain packaging and temperature logs to prevent this issue, but generic suppliers using standard ground shipping frequently deliver degraded product. Once reconstituted, any warm-temperature exposure makes the vial unusable regardless of appearance.

What If Reconstituted KLOW Peptide Develops Cloudiness After One Week?

Discard the vial immediately—cloudiness indicates protein aggregation or bacterial contamination, both of which render KLOW peptide biologically inactive and potentially harmful. Aggregation occurs when peptide bonds denature and clump together, usually triggered by temperature fluctuations, repeated freeze-thaw cycles, or contamination introduced during draws. Bacterial growth appears as cloudiness, visible particulates, or discoloration and can occur if bacteriostatic water was not used or if the stopper was inadequately sterilized before needle insertion. Cloudiness never resolves—the structural damage is permanent. Even if only slightly hazy, the compound should not be used. Proper storage at 2–8°C in amber glass vials with fresh alcohol swabbing before every draw prevents this issue in 95% of cases.

What If You're Combining KLOW Peptide Research With Other Longevity Compounds?

Consult published literature on pathway interactions before combining compounds. KLOW peptide primarily modulates FOXO transcription factors and insulin/IGF-1 signaling, which can potentiate or antagonize effects of other research peptides depending on their mechanisms. For example, combining KLOW peptide with Epithalon Peptide, which activates telomerase and influences epigenetic aging markers, represents a complementary approach targeting distinct longevity pathways. Conversely, combining KLOW peptide with compounds that activate mTOR signaling—such as certain growth hormone secretagogues—may produce antagonistic effects, as Klotho-mediated FOXO activation suppresses mTOR activity. Timing also matters: administering longevity peptides during fasting windows may enhance FOXO and AMPK pathway activation compared to fed-state administration, though this remains an area of active investigation.

What If KLOW Peptide Shows No Measurable Effect in Initial Research Trials?

Verify peptide purity, storage conditions, and dosing protocols before concluding biological inactivity. KLOW peptide's effects manifest through long-term cellular signaling changes—oxidative stress resistance, inflammatory marker reduction, metabolic parameter shifts—not acute observable responses. Research protocols typically require 4–12 weeks of consistent administration to detect statistically significant changes in biomarkers like plasma insulin, inflammatory cytokines (IL-6, TNF-α), or oxidative stress markers (8-OHdG, malondialdehyde). Inadequate dosing is the most common cause of null results: effective concentrations in published animal studies range from 0.01–0.1 mg/kg body weight, scaled from circulating Klotho protein concentrations that correlate with longevity in human cohort studies. Storage degradation represents the second most common cause—peptides stored above 8°C or exposed to light lose bioactivity without visible changes. If initial trials show no effect, request a fresh vial with CoA documentation and repeat the protocol under controlled temperature conditions.

The Evidence-Based Truth About KLOW Peptide

Here's the honest answer: KLOW peptide is not a general anti-aging supplement—it's a targeted tool for researchers investigating one of the only validated biological pathways that extends lifespan across multiple species. The Klotho-FOXO-insulin/IGF-1 axis is real, well-documented, and mechanistically sound. The challenge is that most commercially available "Klotho peptides" are either under-dosed formulations riding the longevity trend or degraded compounds shipped without cold chain protection. If the peptide arrives warm, wasn't synthesized under pharmaceutical-grade conditions, or lacks third-party purity verification, it won't replicate the effects seen in peer-reviewed studies—period.

The second truth: KLOW peptide effects are cumulative and subtle, not immediate and dramatic. Researchers expecting rapid, visible changes will be disappointed. Klotho protein operates at the level of gene transcription, mitochondrial efficiency, and inflammatory regulation—systems that require weeks to months of consistent signaling to shift measurably. The studies showing 19–31% lifespan extension in mice involved lifelong Klotho overexpression, not short-term peptide administration. KLOW peptide research makes sense for investigations into oxidative stress resistance, vascular health, and metabolic dysfunction—domains where months-long protocols and quantitative biomarker measurement are standard. It makes no sense for anyone seeking quick results or relying on subjective self-assessment.

The third reality: quality variance in the peptide research space is extreme. Real Peptides uses small-batch synthesis with exact amino-acid sequencing, HPLC/MS purity verification, and cold chain shipping with temperature monitoring—this is the standard required for reproducible research. Most generic suppliers do none of this. A $40 vial of "KLOW peptide" from an overseas bulk manufacturer is not the same compound as a pharmaceutical-grade formulation, even if both labels claim 5mg. Purity, stability, and bioactivity are not assumptions—they're measurable specifications that determine whether a research protocol succeeds or fails. If the supplier cannot provide a certificate of analysis showing ≥98% purity and <5% peptide-related impurities, the compound quality is unknown and results will be unreliable.

KLOW peptide represents one of the most scientifically credible approaches to longevity research available in 2026—but only when sourced, stored, and administered under conditions that preserve its biological activity. The mechanism is validated. The question is whether the compound in the vial matches the molecule studied in peer-reviewed literature.

Comparison Table Section

(Already included above as "KLOW Peptide: Comparison of Research-Grade Options")

For laboratories and researchers seeking high-purity compounds that meet pharmaceutical-grade standards, Real Peptides offers a curated selection of research peptides with published certificates of analysis and cold chain shipping protocols. Beyond KLOW peptide, researchers investigating complementary longevity pathways often examine Epithalon Peptide for telomerase activation, MOTS-C Peptide for mitochondrial efficiency, and Thymosin Alpha-1 for immune system modulation—each targeting distinct but interconnected mechanisms within cellular aging research. Explore the complete range of research-grade peptides at Real Peptides to find compounds that align with your specific investigation protocols.

If the supplier can't provide a certificate of analysis, the peptide purity is unknown—and unknown purity means unreliable research. Real Peptides publishes CoA documentation for every batch, ensures pharmaceutical-grade lyophilisation, and ships with temperature-monitored cold chain packaging to guarantee the compound arrives with full bioactivity intact. The difference between a successful research protocol and a failed one often comes down to compound quality before the first injection.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions